Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids.

Published

Journal Article

BACKGROUND: Although inhaled corticosteroids (ICSs) are effective in preventing deterioration in asthma control, at least half of subjects with mild-to-moderate asthma will remain stable when these agents are discontinued. OBJECTIVE: We sought to determine whether noninvasive markers of inflammation predict which individuals maintain asthma control after discontinuation of ICSs. METHODS: We analyzed data obtained from 164 subjects with mild-to-moderate asthma who participated in a 16-week trial comparing the effects of continued ICS use with the effects of a switch to salmeterol or placebo. RESULTS: In comparison with continued ICS use, a switch to salmeterol or placebo was associated with increased rates of asthma deterioration over 16 weeks (9.3% vs 24.1% and 37.5%, respectively; P = .04 and P < .001, respectively). We found that neither exhaled nitric oxide nor methacholine PC 20 , when measured at randomization or 2 weeks after randomization, were significant predictors of subsequent asthma control in subjects who discontinued ICSs. However, both induced sputum eosinophil counts measured 2 weeks after a switch from ICS to placebo and changes in sputum eosinophil counts from before cessation of ICSs to after a switch to placebo predicted subsequent asthma deterioration (area under the receiver-operating characteristic curve, 0.771 [ P < .001] and 0.825 [ P < .001], respectively). CONCLUSION: On the basis of a model treatment strategy, we estimate that allocating subjects to ICS therapy on the basis of changes in sputum eosinophil counts after a trial discontinuation could allow 48% of subjects with mild-to-moderate asthma to discontinue ICS therapy without an increased risk of asthma deterioration over a period of at least 14 weeks.

Full Text

Cited Authors

  • Deykin, A; Lazarus, SC; Fahy, JV; Wechsler, ME; Boushey, HA; Chinchilli, VM; Craig, TJ; Dimango, E; Kraft, M; Leone, F; Lemanske, RF; Martin, RJ; Pesola, GR; Peters, SP; Sorkness, CA; Szefler, SJ; Israel, E; Asthma Clinical Research Network, National Heart, Lung, and Blood Institute/NIH,

Published Date

  • April 2005

Published In

Volume / Issue

  • 115 / 4

Start / End Page

  • 720 - 727

PubMed ID

  • 15805990

Pubmed Central ID

  • 15805990

Electronic International Standard Serial Number (EISSN)

  • 1097-6825

International Standard Serial Number (ISSN)

  • 0091-6749

Digital Object Identifier (DOI)

  • 10.1016/j.jaci.2004.12.1129

Language

  • eng